Achieve Life Sciences (ACHV) Depreciation & Amortization (CF) (2010 - 2026)
Achieve Life Sciences' (ACHV) quarterly Depreciation & Amortization (CF) came in at $57000.0 in Q1 2026, down 8.06% YoY from $62000.0 in Q1 2025, and little changed on a QoQ basis from $57000.0 in Q4 2025.
Achieve Life Sciences (ACHV) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $57000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 8.06% year-over-year to $57000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $223000.0 (down 4.7% YoY) and the FY2025 annual result came in at $228000.0, changed 0.44% from the prior year.
- Depreciation & Amortization (CF) steadied at $57000.0 in Q1 2026, from $57000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $65000.0 in Q4 2022 to a low of $54000.0 in Q3 2025.
- A 5-year average of $57529.4 and a median of $57000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) retreated 12.31% — and 2025, when it rose 8.77%.
- Tracing ACHV's Depreciation & Amortization (CF) over 5 years: stood at $65000.0 in 2022, then dropped by 12.31% to $57000.0 in 2023, then advanced by 1.75% to $58000.0 in 2024, then declined by 1.72% to $57000.0 in 2025, then changed by 0.0% to $57000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $57000.0 (Q1 2026), $57000.0 (Q4 2025), and $54000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - | 58,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58,000.00 |
| Jun 30, 2026 | 58,000.00 |
| Mar 31, 2026 | 57,000.00 |
| Mar 31, 2026 | 57,000.00 |
| Dec 31, 2025 | 57,000.00 |
| Dec 31, 2025 | 57,000.00 |
| Sep 30, 2025 | 54,000.00 |
| Sep 30, 2025 | 54,000.00 |
| Jun 30, 2025 | 55,000.00 |
| Jun 30, 2025 | 55,000.00 |
| Mar 31, 2025 | 62,000.00 |
| Mar 31, 2025 | 62,000.00 |
| Dec 31, 2024 | 58,000.00 |
| Dec 31, 2024 | 58,000.00 |
| Sep 30, 2024 | 57,000.00 |
| Sep 30, 2024 | 57,000.00 |
| Jun 30, 2024 | 57,000.00 |
| Jun 30, 2024 | 57,000.00 |
| Mar 31, 2024 | 57,000.00 |
| Mar 31, 2024 | 57,000.00 |